— Avid Bioservices (NASDAQ: CDMO) reported a second-quarter 2020 loss of $0.03 per share versus a loss of $0.05 per share expected.
— Revenue soared by 80% to $18.3 million versus $14.25 million expected. This was driven by an increase in the number of in-process and completed manufacturing runs as a result of growing demand from a more diversified client base.
— As of October 31, 2019, revenue backlog was about $52 million, a decrease of 16% as compared to the first quarter of fiscal 2020. The company expects to recognize the majority of this backlog within the next twelve months.
— The gross margin increased to 18% from 3% in the prior-year quarter. This was primarily attributed to the increased number of manufacturing runs.
— Looking ahead into fiscal 2020, the company confirmed its revenue outlook in the range of $64 million to $67 million. In contrast, analysts expect revenue of $65.38 million for the full year.
— The company launched expanded process development (PD) facilities and services. Also, it expanded the scope of work with multiple existing customers to increase the number of manufacturing batches and/or scale of production.
Earlier we looked into how, during the COVID-19 pandemic, retailers saw changing trends in terms of their assortments and how the acceleration of online shopping led many of them to
Data is at the heart of business innovation. Recognizing this trend, companies are seeking ways to transform their businesses by capturing, analyzing, and mobilizing data. The public cloud is becoming
The second half has been highly rewarding for design software maker Adobe Inc. (NASDAQ: ADBE) amid stable demand for digital content solutions. The company has remained unaffected by the virus-related